Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINKLE: Selumetinib granules in young children with NF1-related plexiform neurofibromas
2023-506357-38-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of selumetinib in neurofibromatosis type 1-associated plexiform neurofibroma (NF1-PN), sponsored by AstraZeneca. Primary endpoints: Selumetinib AUC0-12 after single dose and Safety and tolerability (adverse events and clinical assessments). Planned start May 2024; status: authorised.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1-associated plexiform neurofibroma (NF1-PN)
Beyond the preview
Go deeper on 2023-506357-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506357-38-00.